A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol
Letter
[키워드] 1:1
24 hour
28-day mortality
activated
acute respiratory distress syndrome
Administered
Admission
adverse effect
age
albumin
allergic
allocation concealment
Anticoagulant
apheresis
approval
approved
assessment
Basel
block size
C-reactive protein
category
changes in
city
Coagulopathy
Control
COVID-19
COVID-19 disease
criteria
Cytokine release syndrome
D-dimer
defined
disease
dissemination
drug
eight
element
Enrollment
evaluate
evaluated
ferritin
fibrinogen
first dose
FIVE
food
function
group
ICU
ICU admission
ill patient
Improving
Inc.
Inflammatory
ingredient
intensive care
intensive care unit
International
Intervention
intervention group
intubation
IRB
ISRCTN
KDIGO
King
Kingdom
Laboratory
lack
lactate dehydrogenase
life threatening
life-threatening
Life-threatening COVID-19
marker
measure
Mild
Ministry of Health
Multicenter trial
Multisystem organ failure
National
negative RT-PCR
normalized
number
objective
occur
on mechanical ventilation
Open-label
outcome
Palliative care
participant
Participants
Patient
patients
performed
pilot study
plasma
primary site
Prothrombin time
protocol
Qiagen
randomization
randomize
Randomized
Randomized controlled trial
randomized trial
Real-time PCR
receive
receiving
recommendations
recruit
reduce
replaced
Roche
RT-PCR
RT-PCR kit
Safety
Sample size
SARS CoV-2
SARS-CoV-2
SARS-COV-2 infection
Saudi Arabia
secondary
serum
Seven
sodium
SOFA
status
Stratification
Study protocol
supportive care
Switzerland
System
Therapeutic plasma exchange
therapy
TPE
treatment for COVID-19
tumor necrosis factor-alpha
USA
Volume
website
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04454-4 PMC 바로가기 [Article Type] Letter